Urinary human L-FABP is a potential biomarker to predict COX-inhibitor-induced renal injury

Nephron - Experimental Nephrology

Volumn 108, Issue 1, 2008, Pages

  Tanaka, Tamami ^a   Noiri, Eisei ^a,d   Yamamoto, Tokunori ^b   Sugaya, Takeshi ^c   Negishi, Kousuke ^a   Maeda, Rui ^d   Nakamura, Kazuo ^c   Portilla, Didier ^e   Goto, Momokazu ^b   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY HOSPITAL   (Japan)

^c Strategic and Regulatory Affairs Consulting Department   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Biomarker development; Chronic renal injury; Cyclooxygenase inhibitors; L type fatty acid binding protein

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; FATTY ACID BINDING PROTEIN; MELOXICAM; N ACETYL BETA GLUCOSAMINIDASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY FLOW; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HISTOPATHOLOGY; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY TUBULE PRESSURE; MACROPHAGE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SODIUM RESTRICTION; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL; URINALYSIS;

ANIMALS; BIOLOGICAL MARKERS; CYCLOOXYGENASE INHIBITORS; FATTY ACID-BINDING PROTEINS; HUMANS; KIDNEY; KIDNEY DISEASES; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, INBRED ICR; MICE, TRANSGENIC; PREDICTIVE VALUE OF TESTS;

EID: 39149093392     PISSN: 16602129     EISSN: None     Source Type: Journal    
DOI: 10.1159/000112912     Document Type: Article

References (16)

1. Kramer HJ, Stinnesbeck B, Klautke G, Kipnowski J, Klingmueller D, Glaenzer K, Duesing R: Interaction of renal prostaglandins with the renin-angiotensin and renal adrenergic nervous systems in healthy subjects during dietary changes in sodium intake. Clin Sci (Lond) 1985;68:387-393.
2. Muther RS, Potter DM, Bennett WM: Aspirin-induced depression of glomerular filtration rate in normal humans: role of sodium balance. Ann Intern Med 1981;94:317-321.
3. Cryer B, Feldman M: Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 1998;104:413-421.
4. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol 1998;38:97-120.
5. Gilroy DW, Colville-Nash PR, Willis D, Chivers J, Paul-Clark MJ, Willoughby DA: Inducible cyclooxygenase may have anti-inflammatory properties. Nat Med 1999;5:698-701.
6. Gabriel SE, Jaakkimainen L, Bombardier C: Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-796.
7. Cheng HF, Wang JL, Zhang MZ, Miyazaki Y, Ichikawa I, McKanna JA, Harris RC: Angiotensin II attenuates renal cortical cyclooxygenase-2 expression. J Clin Invest 1999;103:953-961.
8. Cheng HF, Harris RC: Cyclooxygenases, the kidney, and hypertension. Hypertension 2004;43:525-530.
9. Engelhardt G, Bogel R, Schnitzler C, Utzmann R: Meloxicam: influence on arachidonic acid metabolism. II. In vivo findings. Biochem Pharmacol 1996;51:29-38.
10. Yamamoto T, Tada T, Brodsky SV, Tanaka H, Noiri E, Kajiya F, Goligorsky MS: Intravital videomicroscopy of peritubular capillaries in renal ischemia. Am J Physiol Renal Physiol 2002;282:F1150-F1155.
11. Matsumoto M, Tanaka T, Yamamoto T, Noiri E, Miyata T, Inagi R, Fujita T, Nangaku M: Hypoperfusion of peritubular capillaries induces chronic hypoxia before progression of tubulointerstitial injury in a progressive model of rat glomerulonephritis. J Am Soc Nephrol 2004;15:1574-1581.
12. Ogasawara Y, Takehara K, Yamamoto T, Hashimoto R, Nakamoto H, Kajiya F: Quantitative blood velocity mapping in glomerular capillaries by in vivo observation with an intravital videomicroscope. Methods Inf Med 2000;39:175-178.
13. Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, Honda A, Okabe M, Fujino T, Hirata Y, Omata M, Kaneko R, Fujii H, Fukamizu A, Kimura K: Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol 2004;165:1243-1255.
14. Noiri E, Nagano N, Negishi K, Doi K, Miyata S, Abe M, Tanaka T, Okamoto K, Hanafusa N, Kondo Y, Ishizaka N, Fujita T: Efficacy of darbepoetin in doxorubicin-induced cardiorenal injury in rats. Nephron Exp Nephrol 2006;104:e6-e14.
15. Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, Kimura K, Fujita T, Kinukawa T, Taniguchi H, Nakamura K, Goto M, Shinozaki N, Ohshima S, Sugaya T: Renal Ltype fatty acid-binding protein in acute ischemic injury. J Am Soc Nephrol 2007;18:2894-2902.
16. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ: Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002;347:2104-2110.